Cambridge Investment Research Advisors, Inc. Viking Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $27.1 Billion
- Q2 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 25,128 shares of VKTX stock, worth $1.62 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,128
Previous 14,681
71.16%
Holding current value
$1.62 Million
Previous $1.2 Million
10.63%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding VKTX
# of Institutions
442Shares Held
63.3MCall Options Held
6.23MPut Options Held
2.97M-
Vanguard Group Inc Valley Forge, PA10.1MShares$651 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$388 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$330 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.25MShares$145 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$120 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $4.94B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...